To survey hepatitis B virus (HBV) integration in liver cancer genomes, we conducted massively parallel sequencing of 81 HBV-positive and 7 HBV-negative hepatocellular carcinomas (HCCs) and adjacent normal tissues. We found that HBV integration is observed more frequently in the tumors (86.4%) than in adjacent liver tissues (30.7%). Copy-number variations (CNVs) were significantly increased at HBV breakpoint locations where chromosomal instability was likely induced. Approximately 40% of HBV breakpoints within the HBV genome were located within a 1,800-bp region where the viral enhancer, X gene and core gene are located. We also identified recurrent HBV integration events (in ≥4 HCCs) that were validated by RNA sequencing (RNA-seq) and Sanger sequencing at the known and putative cancer-related TERT, MLL4 and CCNE1 genes, which showed upregulated gene expression in tumor versus normal tissue. We also report evidence that suggests that the number of HBV integrations is associated with patient survival.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Center, M.M. & Jemal, A. International trends in liver cancer incidence rates. Cancer Epidemiol. Biomarkers Prev. 20, 2362–2368 (2011).
But, D.Y., Lai, C.L. & Yuen, M.F. Natural history of hepatitis-related hepatocellular carcinoma. World J. Gastroenterol. 14, 1652–1656 (2008).
Ishikawa, T. Clinical features of hepatitis B virus–related hepatocellular carcinoma. World J. Gastroenterol. 16, 2463–2467 (2010).
Bréchot, C., Gozuacik, D., Murakami, Y. & Paterlini-Brechot, P. Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin. Cancer Biol. 10, 211–231 (2000).
Zucman-Rossi, J. & Laurent-Puig, P. Genetic diversity of hepatocellular carcinomas and its potential impact on targeted therapies. Pharmacogenomics 8, 997–1003 (2007).
Gehring, A.J. et al. Profile of tumor antigen–specific CD8 T cells in patients with hepatitis B virus–related hepatocellular carcinoma. Gastroenterology 137, 682–690 (2009).
Shafritz, D.A., Shouval, D., Sherman, H.I., Hadziyannis, S.J. & Kew, M.C. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N. Engl. J. Med. 305, 1067–1073 (1981).
Koshy, R. et al. Integration of hepatitis B virus DNA: evidence for integration in the single-stranded gap. Cell 34, 215–223 (1983).
Brechot, C., Pourcel, C., Louise, A., Rain, B. & Tiollais, P. Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma. Nature 286, 533–535 (1980).
Chakraborty, P.R., Ruiz-Opazo, N., Shouval, D. & Shafritz, D.A. Identification of integrated hepatitis B virus DNA and expression of viral RNA in an HBsAg-producing human hepatocellular carcinoma cell line. Nature 286, 531–533 (1980).
Bonilla Guerrero, R. & Roberts, L.R. The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma. J. Hepatol. 42, 760–777 (2005).
Murakami, Y. et al. Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut 54, 1162–1168 (2005).
Paterlini-Bréchot, P. et al. Hepatitis B virus–related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene 22, 3911–3916 (2003).
Gozuacik, D. et al. Identification of human cancer-related genes by naturally occurring Hepatitis B Virus DNA tagging. Oncogene 20, 6233–6240 (2001).
Saigo, K. et al. Integration of hepatitis B virus DNA into the myeloid/lymphoid or mixed-lineage leukemia (MLL4) gene and rearrangements of MLL4 in human hepatocellular carcinoma. Hum. Mutat. 29, 703–708 (2008).
Ferber, M.J. et al. Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene 22, 3813–3820 (2003).
Neuveut, C., Wei, Y. & Buendia, M.A. Mechanisms of HBV-related hepatocarcinogenesis. J. Hepatol. 52, 594–604 (2010).
Totoki, Y. et al. High-resolution characterization of a hepatocellular carcinoma genome. Nat. Genet. 43, 464–469 (2011).
Li, M. et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat. Genet. 43, 828–829 (2011).
Furuta, T. et al. Clinicopathologic features of hepatocellular carcinoma in young patients. Cancer 66, 2395–2398 (1990).
Kim, J.H. et al. Clinical features and prognosis of hepatocellular carcinoma in young patients from a hepatitis B–endemic area. J. Gastroenterol. Hepatol. 21, 588–594 (2006).
Hao, K. et al. Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters. BMC Cancer 9, 389 (2009).
Xu, X. et al. The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line. Nat. Biotechnol. 29, 735–741 (2011).
Chen, Y. et al. Complete genome sequence of hepatitis B virus (HBV) from a patient with fulminant hepatitis without precore and core promoter mutations: comparison with HBV from a patient with acute hepatitis infected from the same infectious source. J. Hepatol. 38, 84–90 (2003).
Trapnell, C., Pachter, L. & Salzberg, S.L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105–1111 (2009).
Mortazavi, A., Williams, B.A., McCue, K., Schaeffer, L. & Wold, B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat. Methods 5, 621–628 (2008).
Lamb, J.R. et al. Predictive genes in adjacent normal tissue are preferentially altered by sCNV during tumorigenesis in liver cancer and may rate limiting. PLoS ONE 6, e20090 (2011).
Chiang, D.Y. et al. High-resolution mapping of copy-number alterations with massively parallel sequencing. Nat. Methods 6, 99–103 (2009).
Mermel, C.H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).
We gratefully acknowledge Y.-K. Mak and the clinical team of the Division of Hepatobiliary and Pancreatic Surgery (HBP) at Queen Mary Hospital. This study was funded by the Asian Cancer Research Group (ACRG), a not-for-profit organization formed by Eli Lilly, Merck and Pfizer. We thank S. Friend and G. Jin for initiating the establishment of ACRG. We are grateful to former and present members of ACRG, especially K. Blanchard, Y. Turpaz, J. Sedgwick, G. Tucker-Kellogg, G. Gilliland, P. Shaw, N. Gibson and S. Adams.
The authors declare no competing financial interests.
Supplementary Figures 1–8, Supplementary Table 1 and Supplementary Note (PDF 1422 kb)
Summary of sequencing depth and coverage of 88 (TU/AN) pairs of HCC. (XLS 46 kb)
Characterization of 399 HBV integration breakpoints identified in HCC. (XLS 139 kb)
Validation result for the HBV integration sites. (XLS 40 kb)
Correlation analysis of HBV integration (cutoff = 1 to 6) with various clinic-pathological parameters of HCC patients (n = 83). (XLSX 13 kb)
About this article
Cite this article
Sung, WK., Zheng, H., Li, S. et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet 44, 765–769 (2012). https://doi.org/10.1038/ng.2295
Hepatitis B Virus–Telomerase Reverse Transcriptase Promoter Integration Harnesses Host ELF4, Resulting in Telomerase Reverse Transcriptase Gene Transcription in Hepatocellular Carcinoma
C-terminal truncated HBx initiates hepatocarcinogenesis by downregulating TXNIP and reprogramming glucose metabolism
Nucleic Acids Research (2021)
Multiple Roles for Hepatitis B and C Viruses and the Host in the Development of Hepatocellular Carcinoma
Hepatitis B Virus DNA Integration: In Vitro Models for Investigating Viral Pathogenesis and Persistence